116 completed, 20 unknown, 13 not yet recruiting, 8 recruiting. 55 Phase 3, 33 Phase 2, 26 Not applicable, 20 Phase 1, 17 Phase 4.
Follow Togaviridae Infections: new trials by email Literature Review of Togaviridae Infections trials Research Report on Togaviridae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Against Chikungunya Virus and Neonatal Infection plasma transfusion : PC-CHIK-V - Chikungunya Virus Infection, Neonatal | Not applicable | Recruiting | Centre Hospitalier Universitaire de la Réunion | 60 | 2027-08-01 | 2026-09-15 |
| Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555) - Dengue, Chikungunya | Phase 3 | Not yet recruiting | Butantan Institute | 900 | 2027-03-31 | 2026-07-16 |
| Evaluation of IXCHIQ® Vaccine Immunogenicity IXCHIQ vaccine - Healthy Adult, Healthy Adolescents | Phase 2 | Not yet recruiting | Mauro Martins Teixeira | 75 | 2026-09-24 | 2026-09-29 |
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine - Measles, Mumps | Phase 3 | Not yet recruiting | GlaxoSmithKline | 1860 | 2026-08-11 | 2026-08-03 |
| Smart Analysis and Decision-Making for Emerging Infectious Diseases Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices - Emerging Infectious Diseases, COVID-19 | Not applicable | Enrolling by invitation | Peking University | 108 | 2026-08-10 | 2026-08-19 |
| A Phase I Study of PepGNP-ChikV in Healthy Volunteers PepGNP-ChikV, Placebo - Chikungunya, Chikungunya Fever | Early Phase 1 | Not yet recruiting | Gylden Pharma Ltd | 40 | 2026-08-03 | 2026-04-29 |
| Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients Exercise - Dengue, Chikungunya | Not applicable | Not yet recruiting | Universidade do Estado do Pará | 54 | 2026-07-01 | 2026-05-26 |
| VLA1553-403 Pregnancy Surveillance Study Live-attenuated CHIKV vaccine VLA1553, Vaccine(s) approved for use during pregnancy by the MoH - Chikungunya Virus Infection | Enrolling by invitation | Valneva Austria GmbH | 200 | 2026-06-11 | 2026-07-20 | |
| An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults CHIKV VLP vaccine, Placebo - Chikungunya Virus | Phase 3 | Recruiting | Bavarian Nordic | 6144 | 2026-05-26 | 2026-06-29 |
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age MMRVNS, MMRV - Measles, Measles-Mumps-Rubella+Chickenpox Vaccine | Phase 3 | Recruiting | GlaxoSmithKline | 1209 | 2026-05-11 | 2026-07-08 |
| A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age. BBV87 Chikungunya vaccine, Placebo - Active Immunisation for Chikungunya Virus Infection | Phase 2 / Phase 3 | Recruiting | Bharat Biotech International Limited | 1000 | 2026-04-20 | 2026-04-29 |
| Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian Communities Full intervention, Partial intervention - Dengue, Zika | Not applicable | Completed | University of Freiburg | 900 | 2026-03-26 | 2026-04-08 |
| A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children VLA1553, Control - Chikungunya Virus Infection | Phase 3 | Withdrawn | Valneva Austria GmbH | 2026-02-06 | 2025-12-31 | |
| Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil Live-attenuated CHIKV vaccine VLA1553 - Chikungunya Virus Infection | Active not recruiting | Valneva Austria GmbH | 5000 | 2026-02-02 | 2026-07-21 | |
| Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil Live-attenuated CHIKV vaccine VLA1553 - Chikungunya Virus Infection | Enrolling by invitation | Valneva Austria GmbH | 1200 | 2026-02-02 | 2026-07-17 | |
| the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines Polio, Measles | Not yet recruiting | China National Biotec Group Company Limited | 600 | 2026-01-30 | 2026-01-14 | |
| Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective Dengue, Chikungunya | Recruiting | Institut Pasteur du Cambodge | 10000 | 2025-12-18 | 2026-01-22 | |
| Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil Live-attenuated CHIKV vaccine VLA1553 - Chikungunya Virus Infection | Active not recruiting | Valneva Austria GmbH | 5354 | 2025-09-22 | 2026-02-11 | |
| Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients Commercial measles, mumps, and rubella (MMR) vaccine - Heart Transplant Infection Prevention | Phase 4 | Recruiting | Children's Mercy Hospital Kansas City | 60 | 2025-09-11 | 2026-09-24 |
| Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections Exanthema, Dengue Fever | Not yet recruiting | Hospital Israelita Albert Einstein | 830 | 2025-09-01 | 2025-08-08 |
Showing 20 of 183. Sign in to see all of them.
Chikungunya Fever (88) · Measles (82) · Rubella (82) · Mumps (69) · Chickenpox (44) · Dengue (31) · Zika Virus Infection (27) · Encephalomyelitis, Venezuelan Equine (8) · Malaria (8) · Arbovirus Infections (7) · Alphavirus Infections (5) · Encephalitis, Japanese (5) · Haemophilus Infections (5) · Encephalitis (4) · Hepatitis A (4)
Infections (183) · RNA Virus Infections (182) · Virus Diseases (179) · Mosquito-Borne Diseases (106) · Vector Borne Diseases (104) · Arbovirus Infections (101) · Alphavirus Infections (98) · Mononegavirales Infections (83) · Morbillivirus Infections (82) · Paramyxoviridae Infections (82) · Rubivirus Infections (82) · Mouth Diseases (69) · Parotid Diseases (69) · Parotitis (69)
measles, mumps, rubella, varicella vaccine (21) · Measles-Mumps-Rubella Vaccine (18) · Chickenpox Vaccine (9) · Hepatitis A Vaccines (7) · Rubella Vaccine (7) · Vaccines (7) · Blood Specimen Collection (5) · Heptavalent Pneumococcal Conjugate Vaccine (4) · Vaccines, Attenuated (4) · 13-valent pneumococcal vaccine (3) · Desiccation (3) · Meningococcal Vaccines (3) · CRM197 (non-toxic variant of diphtheria toxin) (2) · Exercise (2) · Priorix-Tetra vaccine (2)
GlaxoSmithKline (22) · Merck Sharp & Dohme LLC (18) · National Institute of Allergy and Infectious Diseases (NIAID) (11) · Valneva Austria GmbH (11) · Bavarian Nordic (9) · Centre Hospitalier Universitaire de la Réunion (6) · U.S. Army Medical Research and Development Command (6) · Sanofi Pasteur, a Sanofi Company (5) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (5) · Themis Bioscience GmbH (4) · Institut Pasteur (3) · Bharat Biotech International Limited (2) · Butantan Institute (2) · Centers for Disease Control and Prevention, China (2) · Centre Hospitalier Universitaire de la Guadeloupe (2)
United States (51) · Brazil (19) · France (14) · Germany (12) · Puerto Rico (11) · China (9) · Colombia (7) · Taiwan (7) · Italy (6) · Mexico (6) · Finland (5) · Reunion (5) · Guadeloupe (4) · Thailand (4) · Austria (3)
Myrielle Dupont-Rouzeyrol, PhD (3) · Patrick Ajiboye, MD (3) · Andre Cabie, MD (2) · Anthony Cardile, DO (2) · Clemente Diaz, MD (2) · Grace Chen, MD (2) · James McCarty, MD (2) · Robert Rivard, MD (2)
PMID 35709798, PMID 31878895, PMID 32497524, PMID 33422034, PMID 37254133, PMID 37321235, PMID 16094218, PMID 16452343, PMID 16567978, PMID 16804432, PMID 17332177, PMID 17502347, PMID 19305145, PMID 19366435, PMID 20955461, PMID 22123890, PMID 22406278, PMID 22772170, PMID 25132507, PMID 25739878, PMID 25765966, PMID 26362659, PMID 27149048, PMID 27206386, PMID 27423382, PMID 27694629, PMID 27705091, PMID 28481690, PMID 29266856, PMID 29855331, PMID 29902133, PMID 30409443, PMID 30481110, PMID 30572920, PMID 30833160, PMID 31481612, PMID 31672665, PMID 32163420, PMID 32220283, PMID 32286643, PMID 32450914, PMID 33686914, PMID 33828518, PMID 33836004, PMID 33899755, PMID 34107180, PMID 34330906, PMID 34454432, PMID 34529649, PMID 34582377
2025 (3), 2014 (2), 2015 (1), 2018 (1), U01AI148069 (1), U44AI152995 (1)